PROK Insider Trading
Insider Ownership Percentage: 41.49%
Insider Buying (Last 12 Months): $74,735,337.82
Insider Selling (Last 12 Months): $345,310.61
ProKidney Share Price & Price History
Current Price: $0.73
Price Change: ▲ Price Increase of +0.1178 (19.20%)
As of 04/11/2025 05:00 PM ET
ProKidney Insider Trading History
ProKidney Institutional Trading History
Data available starting January 2016
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Read More on ProKidney
Volume
606,347 shs
Average Volume
690,080 shs
Market Capitalization
$214.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.52
Who are the company insiders with the largest holdings of ProKidney?
Who are the major institutional investors of ProKidney?
Which major investors are buying ProKidney stock?
During the previous quarter, PROK stock was acquired by institutional investors including:
- Hennion & Walsh Asset Management Inc.
In the previous year, these company insiders have bought ProKidney stock:
- Control Empresarial De Capital (Insider)
- Pablo G Legorreta (Director)
Learn More investors buying ProKidney stock.